Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - December 6, 2001
Under the agreement, Esoterix's sales representatives will promote ViroLogic's PhenoSense line of HIV drug resistance tests. Esoterix Infectious Disease Center currently serves a national network of reference and hospital- based laboratories.
"This agreement should further increase awareness and expand availability of our tests, which make up the most comprehensive line available in the industry," said Bill Young, ViroLogic's Chairman and Chief Executive Officer.
"We look forward to working closely with Esoterix to educate physicians and other caregivers about the benefits of HIV resistance testing in general and our tests in particular."
HIV drug resistance is a rapidly growing problem that is jeopardizing the success of AIDS therapy for the nearly 500,000 Americans being treated with antiviral drugs for HIV infection. Widespread resistance to these drug regimens is greatly complicating treatment for these patients, especially those who have been on treatment for many years and have developed resistance to individual drugs, or even to entire classes of therapy.
"ViroLogic's state-of-the-art HIV PhenoSense drug resistance tests will add tremendous value to our current clients, and help us penetrate this fast-growing part of the patient testing market," said Ted E. Schutzbank, Ph.D., Chief Scientific Officer for the Esoterix Infectious Disease Center.
"Our customers are demanding the kind of advanced, easy-to- interpret information that ViroLogic's tests provide."
About Esoterix
Esoterix Infectious Disease Center is a specialized provider of laboratory services focused exclusively on assisting clients in diagnosing, monitoring and treating patients with microbial diseases. Esoterix Infectious Disease Center is part of the Esoterix Inc. family of laboratories. Founded in 1995, Esoterix, Inc. is a unique company providing technology-based laboratory services and information solutions to enhance healthcare providers' ability to manage and care for patients. Esoterix's testing services include expertise in Allergy and Asthma, Coagulation/Hematology, Endocrinology, Molecular Genetics, Oncology, and Toxicology. Esoterix also has a central laboratory, The Esoterix Center for Clinical Trials, dedicated to biopharmaceutical research. Esoterix has 580 employees and is privately funded through Behrman Capital of New York. (http://www.esoterix.com).
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized medicine and pharmacogenomics, helping to make them realities in healthcare around the world today. The Company discovers, develops and markets innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. Its leading expertise in virology, molecular biology, clinical research, engineering, information systems, and quality assurance has resulted in technology to assess drug resistance and susceptibility in viruses that cause these diseases, which affect millions of people worldwide.
The Company's current products are designed to optimize HIV/AIDS treatment regimens, providing physicians with important information to help select appropriate drugs for their patients and leading to better outcomes and reduced costs. Major pharmaceutical companies to develop new and improved antiviral therapeutics targeted at emerging drug-resistant viruses are also using these products. More information about the Company and its technologies is available at http://www.virologic.com or http://www.phenosense.com.
Certain statements in this press release are forward-looking, including statements relating to the Company's product development efforts. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to whether ViroLogic's products will achieve market acceptance, whether payers will authorize reimbursement for our products, whether we will be able to expand our sales and marketing capabilities, whether the FDA or any other agency will decide to regulate our products or services, whether we will encounter problems or delays in automating our process, whether we will successfully introduce new products using our PhenoSense technology, whether intellectual property underlying our technology is adequate, whether we are able to build brand loyalty, whether we will be able to raise sufficient capital and other risks and uncertainties detailed from time to time in our reports to the Securities and Exchange Commission, including our report on Form 10-K for the year ended December 31, 2000.
SOURCE ViroLogic, Inc. Web Site: http://www.virologic.com http://www.phenosense.com http://www.esoterix.com
011206
PR011210
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .